SCHEDULE: EcoR1 Capital Discloses 9.9% Stake in iBio, Inc.

EcoR1 Capital, LLC and its principal Oleg Nodelman have disclosed a 9.9% beneficial ownership stake in iBio, Inc. common stock.

Summary

• EcoR1 Capital, LLC, a Delaware limited liability company, reported beneficial ownership of 2,228,000 shares of iBio, Inc. Common Stock, representing 9.9% of the class.
• Oleg Nodelman, identified as the control person of EcoR1 Capital, LLC, also reported beneficial ownership of 2,228,000 shares, equating to 9.9% of the class.
• EcoR1 Capital Fund Qualified, L.P., a Delaware limited partnership, reported beneficial ownership of 2,091,422 shares, representing 9.3% of the class.
• The percentages are calculated based on 22,487,308 shares of Common Stock outstanding on November 10, 2025, as reported in iBio, Inc.'s Form 10-Q for the quarter ended September 30, 2025.
• All reporting persons hold shared voting and dispositive power over their reported shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant 9.9% stake by a reputable institutional investor like EcoR1 Capital is generally a positive signal, indicating confidence in the company's value or future prospects. This suggests a favorable view from a sophisticated market participant.

Positives

• A significant institutional investor, EcoR1 Capital, LLC, and its principal, Oleg Nodelman, have disclosed a substantial 9.9% stake in iBio, Inc., signaling potential confidence in the company's future prospects.
• The investment is stated to be in the ordinary course of business, suggesting a long-term investment perspective rather than an activist intent to influence control.

Future Outlook

This filing does not contain forward-looking statements or guidance from iBio, Inc. It solely reports beneficial ownership by an external entity.

Industry Context

The disclosure of a significant stake by a specialized healthcare investment firm like EcoR1 Capital in a biotechnology company like iBio, Inc. can be viewed as a positive indicator within the industry, potentially attracting further investor interest. Such filings are common for institutional investors accumulating positions in public companies.

Stakeholder Impact

• Shareholders may view the significant institutional ownership as a positive endorsement, potentially leading to increased investor confidence and demand for the stock.
• The company's management might perceive this as validation of their strategy and operations, potentially influencing future strategic decisions or investor relations efforts.

Key Dates

Recommendation

The filing indicates a significant institutional stake by EcoR1 Capital, which is a positive signal of investor confidence. However, a Schedule 13G filing primarily reports ownership and does not provide detailed financial performance, operational updates, or strategic guidance. While the institutional interest is noteworthy, it is insufficient on its own to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and conduct further due diligence on iBio, Inc.'s fundamentals, pipeline, and market position to make an informed investment decision.

Keywords

iBio Inc, EcoR1 Capital, Oleg Nodelman, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Biotechnology